AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo
Systemic reactogenicity events
AD26.COV2.S – Janssen Pharmaceutical Companies leads to higher systemic reactogenicity eventse compared with placebo (high certainty).
1 finding from 1 review
- RR 1.83 [1.29, 2.6]2 studies · 7222 participantsHigh